目的 探讨血清中补体因子B、Toll样受体4(TLR4)对妊娠期糖尿病患者发生子痫前期风险的预测价值。方法 2022年5月至2023年5月,从本院就诊的妊娠期糖尿病患者中选取100例作为研究组,另选同期就诊的100例健康妊娠的患者作为对照组,对照组年龄为21～38岁,孕周为21～36周;研究组年龄为22～39岁,孕周为22～37周;研究组按照有无子痫前期分为无子痫前期组68例,有子痫前期组32例;按照子痫前期不同程度分为轻度组12例,中度组11例,重度组9例;检测血清补体因子B、TLR4水平,分析其与妊娠期糖尿病患者发生子痫前期的关系及其风险预测价值。结果 与对照组相比,研究组血清中补体因子B、TLR4水平明显升高,组间差异有统计学意义;与无子痫前期组相比,有子痫前期组血清中补体因子B、TLR4水平明显升高,组间差异有统计学意义;与轻度组相比,中度组、重度组血清中补体因子B、TLR4水平明显升高,且重度组明显高于中度组,组间差异有统计学意义。二元Logistic回归分析显示,血清中补体因子B、TLR4均为妊娠期糖尿病患者发生子痫前期的风险因素;血清补体因子B检测的AUC为0.736,血清TLR4为0.697,联合为0.845。结论 血清中补体因子B、TLR4是妊娠期糖尿病患者发生子痫前期的风险因素,对妊娠期糖尿病患者发生子痫前期具有预测价值。
关键词
补体因子B /
TLR4 /
妊娠期糖尿病 /
子痫前期 /
预测价值
{{custom_keyword}} /
中图分类号：
R71
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
1 Gal A,Burchell RK.Diabetes Mellitus and the Kidneys.Vet Clin North Am Small Anim Pract,2023,53:565-580.
2 Simmons D,Immanuel J,Hague WM,et al.Treatment of Gestational Diabetes Mellitus Diagnosed Early in Pregnancy.N Engl J Med,2023,388:2132-2144.
3 Deer E,Herrock O,Campbell N,et al.The role of immune cells and mediators in preeclampsia.Nat Rev Nephrol,2023,19:257-270.
4 Paulsen CP,Bandak E,Edemann-Callesen H,et al.The Effects of Exercise during Pregnancy on Gestational Diabetes Mellitus,Preeclampsia,and Spontaneous Abortion among Healthy Women-A Systematic Review and Meta-Analysis.Int J Environ Res Public Health,2023,20:6069.
5 Xue Y,Yang N,Ma L,et al.Predictive value of the complement factors B and H for women with gestational diabetes mellitus who are at risk of preeclampsia.Pregnancy Hypertens,2022,30:210-214.
6 Li T,Wang W,Li S,et al.Lusianthridin Exerts Streptozotocin-Induced Gestational Diabetes Mellitus in Female Rats via Alteration of TLR4/MyD88/NF-κB Signaling Pathway.J Oleo Sci,2023,72:775-785.
7 邵大祥.糖化血红蛋白、血清C肽联合检测在糖尿病诊断中的价值.临床医学研究与实践,2023,8:85-88.
8 刘嘉慧,刘靖.2023年欧洲高血压学会新版高血压管理指南简评.中华高血压杂志,2023,31:908-910.
9 Retnakaran R,Ye C,Hanley AJ,et al.Treatment of Gestational Diabetes Mellitus and Maternal Risk of Diabetes After Pregnancy.Diabetes Care,2023,46:587-592.
10 Liu YH,Zhang YS,Chen JY,et al.Comparative effectiveness of prophylactic strategies for preeclampsia:a network meta-analysis of randomized controlled trials.Am J Obstet Gynecol,2023,228:535-546.11 Samanth R,Shenoy V,Sreedharan S,et al.Effect of Preeclampsia and Gestational diabetes mellitus on Neonatal Distortion Product Otoacoustic Emissions:A Tertiary Care Center Study.Ann Otol Rhinol Laryngol,2023,132:985-995.
12 Qin Y,Bily D,Aguirre M,et al.Understanding PPARγ and Its Agonists on Trophoblast Differentiation and Invasion:Potential Therapeutic Targets for Gestational Diabetes Mellitus and Preeclampsia.Nutrients,2023,15:2459.
13 Xie Y,Zhou W,Tao X,et al.Early Gestational Blood Markers to Predict Preeclampsia Complicating Gestational Diabetes Mellitus.Diabetes Metab Syndr Obes,2023,16:1493-1503.
14 王宝君,郭翔宇,胡燕,等.2型糖尿病患者交感皮肤反应、神经传导速度与空腹血清C肽、FGF21、补体因子B水平相关性研究.临床和实验医学杂志,2022,21:2167-2170.
15 Shen Y,Li J,Tian H,et al.High level of complement factor Ba within first prenatal test of gestation increases the risk of subsequent gestational diabetes:a propensity score-matched study.Gynecol Endocrinol,2022,38:158-163.
16 Liu T,Zheng W,Wang L,et al.TLR4/NF-κB Signaling Pathway Participates in the Protective Effects of Apocynin on Gestational Diabetes Mellitus Induced Placental Oxidative Stress and Inflammation.Reprod Sci,2020,27:722-730.
17 任春丽,唐兴国,张玉芳,等.血清TLR4及MFG-E8与子痫前期患者表达及发生早期肾损伤的关系.中国实验诊断学,2020,24:1770-1773.
18 吕靖,冯泰山,阿衣古丽·斯马依力.IgG和补体C3联合子宫动脉血流在高危孕妇子痫前期诊断中的临床应用研究.中国妇幼保健,2023,38:751-754.
19 王玲.NF-κB和TLR4在子痫前期患者血清中的表达及其诊断意义.中国处方药,2019,17:161-162.
20 He YD,Xu BN,Wang ML,et al.Dysregulation of complement system during pregnancy in patients with preeclampsia:A prospective study.Mol Immunol,2020,122:69-79.
21 黄巧明.PAPP-A、AFP、NF-κB、TLR4及uE3在子痫前期患者血清中的表达及临床意义.中国现代药物应用,2019,13:64-65.
22 李柯瑾,赵玉荣,杜金龙,等.补体B因子与补体H因子对妊娠期糖尿病患者并发子痫前期预测价值.临床军医杂志,2023,51:638-640.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
PDF(374 KB)
